Closing prices for 09 October 2026
Next earnings report: 29 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Edwards Lifesciences Corporation trades on NYSE under the ticker EW. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks EW has traded between 72.30 $ and 96.29 $. As of 09 October 2026 the price stood 53.81 % of the way from the 52-week low to the high.
Over one year EW shares rose 12.50 %; over six months they rose 9.43 %. Volatility over 90 days is 24.06 %. Dividends are not included: this is price change only, as of 09 October 2026.
EW trades at a price-to-earnings ratio of 43.9, above the sector median of 24.8. Price to sales is 7.6, above the sector median of 3.9. Price to book is 4.7, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 84.60 | 85.34 | 83.22 | 85.21 | 4M |
| 08 October 2026 | 85.65 | 85.78 | 82.43 | 84.24 | 7M |
| 07 October 2026 | 86.65 | 87.30 | 85.49 | 85.78 | 4M |
| 06 October 2026 | 87.54 | 87.88 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Edwards Lifesciences makes heart valves implanted through a catheter rather than in open surgery.
Replacing an aortic valve without opening the chest changed treatment: the procedure became available to elderly patients for whom surgery was contraindicated. The company created that market and holds a large share of it, while the eligible patient pool grows with an ageing population.
Revenue follows procedure volume, hence clinic throughput and the availability of trained physicians. The growth line is valves for other parts of the heart, where the technology is harder and competition is only forming. Risks: clinical trial results and insurer reimbursement decisions. The company pays no dividend.
Address:ONE EDWARDS WAY, IRVINE, CA, 92614, US
Edwards Lifesciences Corporation reported revenue of 6.3B $ and net income of 1.1B $ over the last four quarters. Net margin is 17.42 %. Revenue changed by +14.15 % year over year. Earnings per share are 1.88 $. Market capitalisation is 48.2B $.
EW has a return on equity of 10.63 %, above the sector median of −41.68 %. Return on assets is 8.24 %, above the sector median of −32.11 %. Operating margin is 21.37 %, above the sector median of −26.84 %.
| 139M |
| SNNSmith & Nephew SNATS, Inc. | 27.21 | +0.91 % | 46M |
| MSAMSA Safety Incorporated | 180.71 | +1.47 % | 45M |
| ENOVEnovis Corporation | 17.69 | +1.49 % | 36M |
| ESTAEstablishment Labs Holdings Inc. | 61.58 | +1.60 % | 24M |
| 85.94 |
| 86.48 |
| 3M |
| 05 October 2026 | 85.64 | 87.57 | 85.34 | 87.23 | 3M |
| 02 October 2026 | 85.52 | 86.48 | 84.66 | 85.15 | 2M |
| 01 October 2026 | 85.99 | 86.84 | 84.49 | 85.19 | 3M |
| 30 September 2026 | 87.16 | 87.49 | 85.72 | 86.32 | 5M |
| 29 September 2026 | 85.70 | 88.19 | 85.70 | 88.08 | 3M |
| 28 September 2026 | 86.00 | 87.33 | 85.56 | 86.83 | 3M |
| 25 September 2026 | 86.66 | 87.11 | 84.93 | 86.29 | 4M |
| 24 September 2026 | 86.54 | 87.12 | 85.63 | 85.73 | 4M |
| 23 September 2026 | 88.70 | 88.79 | 86.06 | 86.82 | 4M |
| 22 September 2026 | 89.00 | 89.66 | 88.50 | 88.78 | 4M |
| 21 September 2026 | 88.34 | 88.59 | 87.77 | 88.34 | 3M |
| 18 September 2026 | 88.03 | 88.77 | 87.47 | 88.26 | 4M |
| 17 September 2026 | 89.21 | 89.58 | 88.00 | 88.25 | 4M |
| 16 September 2026 | 84.99 | 89.70 | 84.84 | 89.28 | 5M |
| 15 September 2026 | 85.03 | 86.03 | 84.47 | 85.74 | 4M |
| 14 September 2026 | 85.45 | 86.26 | 85.12 | 85.52 | 3M |